InBrain Neuroelectronics Archives - Medical Design Sourcing

InBrain Neuroelectronics leads project to ‘revolutionize’ BCI landscape

The graphene-based, high-resolution cortical brain interface. [Image courtesy of InBrain Neuroelectronics]InBrain Neuroelectronics is leading the GphT-BCI project that it believes could revolutionize the landscape of brain-computer interfaces (BCIs).

The company partnered with the Catalan Institute of Nanoscience and Nanotechnology (ICN2) for the project. It addresses the limitations currently faced by BCIs as researchers look to bring the technology from the lab to commercial settings.

According to the project’s website, the absence of a technology platform combining all necessary properties for building accurate and scalable BCIs has been a “significant hurdle.” That’s where InBrain and ICN2 come in.

InBrain plans for the project to mature a novel type of graphene-based transistors. Already validated in preclinical settings, the graphene-based transistors offer multiplexing capabilities and sensitivity across frequencies. It requir…

5 more brain-computer interface companies you need to know

BCI technology from Cognixion, Precision Neuroscience, InBrain Neuroelectronics and Kandu Health.

The brain-computer interface (BCI) space continues to rise in notoriety, and a number of players are throwing their hats in the ring.

Such technologies could enable users to control a computer with their brain, or even go beyond that. Countless immobile people someday could control a mouse cursor, keyboard, mobile device/tablet, wheelchair or prosthetic device by only thinking.

Big names have already established their presence in the space. Elon Musk’s Neuralink continues to make headway, while Bill Gates- and Jeff Bezos-backed Synchron has an innovative catheter-delivered implant. Blackrock Neurotech, which has a next-generation BCI, has been implanting its Utah Array in patients since 2004.

Those companies and more were covered in last year’s roundup of brain-computer interface companies you need to know. But there are several more companies ou…

InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system

The graphene-based, high-resolution cortical brain interface. [Image courtesy of InBrain Neuroelectronics]InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent network modulation system.

The breakthrough nod covers the graphene-neural platform as an adjunctive therapy for treating Parkinson’s disease.

InBrain’s system harnesses the power of graphene, a two-dimensional material made of a lattice of carbon atoms. The thin material — stronger than steel, the company says — utilizes a combination of electrical and mechanical properties.

According to InBrain, the neural platform enables ultra-high signal resolution, using machine learning software to decode therapy-specific biomarkers. It delivers highly focused, adaptive neuroelectronic therapy that re-balances pathological neural networks.

The semiconductor-derived brain-computer interface (BCI) technology could decode and modulate …

InBrain raises nearly $17M for graphene-based neuromod system

InBrain Neuroelectronics today announced $16.8 million in Series A funding for its neuroelectronic system designed to treat epilepsy and Parkinson’s disease.

The investment in the Barcelona-based company was co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures and TruVenturo GmbH. The Spanish Ministry of Science’s CDTI also participated, as did the Institut Català de Finances’ ICF Venture Tech II fund, which provided a follow-on investment.

Get the full story on our sister site, Medical Design & Outsourcing.